Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Qureight
Deal Size : Undisclosed
Deal Type : Partnership
Cumberland Teams with Qureight to Advance IPF Treatment Research
Details : The partnership will enhance the outcome and output of data from Cumberland's Phase II study evaluating ifetroban product candidate in patients with idiopathic pulmonary fibrosis (IPF).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 13, 2025
Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Qureight
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cumberland’s Phase 2 FIGHT DMD Trial Shows Breakthrough Results in DMD Heart Disease
Details : Dyscorban (ifetroban) is a once-daily oral medication that works by blocking the thromboxane receptor, being investigated for duchenne muscular dystrophy.
Product Name : Dyscorban
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2025
Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cumberland Pharma Receives FDA Orphan Drug Designation for Duchenne Dystrophy Treatment
Details : Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist being investigated for cardiomyopathy associated with Duchenne muscular dystrophy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2024
Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist. Ifetroban exhibits high affinity for TPr on many cell types including platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Ifetroban Sodium
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable